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Hypertension, or high blood pressure (BP), is an ever-growing epidemic in the 
developing world. Understanding the genetics behind essential hypertension (EH), or 
hypertension with no known cause, is especially important. In this study, three single 
nucleotide polymorphisms (SNPs) known to be linked to an increase in susceptibility to 
EH were quantified from a cohort of Kenyans living in the Kasigau region. The SNPs are 
located in three genes that are part of the renin angiotensin system, the primary regulatory 
pathway in humans controlling BP. They include: AGT (rs699), AGTR1 (rs5186), and 
HSD11β2 (rs5479). Overall, by using a fluorescent-based RT-PCR technique, the 
genotype distribution of AGT (rs699) was 0.63 C/C, 0.34 C/T, and 0.03 T/T. When 
evaluated as normotensive, prehypertensive, Stage I, or Stage II categories the allele 
frequencies for f(C)= 0.77,0.85,0.81, 0.77, respectively, and demonstrated Hardy 
Weinberg Equilibrium (HWE) as assessed by Χ2, p < 0.05. The genotype distribution of 
AGTR1 (rs5186) was 0.96 A/A, 0.03 A/C, and 0.00 C/C and the genotype distribution of 
HSD11β2 (rs5479) was 0.46 A/A, 0.46 A/C, and 0.08 C/C. The majority of genotype 
frequencies for each SNP were in HWE, with the exception of the AGT (rs699) SNP 
found in the sublocation of Bughuta suggesting other evolutionary selective pressures 
may be at work in this subpopulation. The high prevalence of the susceptible C allele for 
AGT (rs699) likely implies it is a critical factor in the high prevalence of EH observed in 
this population. 
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INTRODUCTION 
Cardiovascular disease (CVD), a group of disorders of the heart and blood 
vessels, accounts for an estimated 17,300,000 deaths worldwide a year (World Health 
Organization, 2011). These diseases are further categorized into coronary heart disease, 
cerebrovascular disease, peripheral arterial disease, deep vein thrombosis and pulmonary 
embolism, congenital heart disease, and rheumatic heart disease. Acute events such as 
heart attack and stroke are also included as cardiovascular conditions. It is estimated that 
over 80% of the deaths from CVD take place in low- and middle-income countries and 
occur almost equally in men and women (Mathers & Loncar, 2006). Additionally, ethnic 
differences also can differentially contribute to CVD. Essential hypertension (EH) is 
considered to be a major modifiable risk factor for the development of CVD (Edwards, 
Unwin, & Mugusi, 2000), and EH is the leading risk factor for CVD. EH can also even 
lead to premature death (Doris, 2002). EH is a heterogeneous disorder with many 
different causal factors leading to its diagnosis; no single genetic or risk factor can 
determine its severity. Therefore, there is a great need for research into the causes of EH.  
EH has various degrees of severity and is based primarily on blood pressure (BP) 
(Tobin, Sheehan, Scurrah, & Burton, 2005). Since BP is a ratio of systolic to diastolic 
rates, the clinical aspects of classification is determined by two different numbers based 
on these rates (Tobin et al., 2005). There are three categories of EH classification in 
addition to normal individuals. The first, and least severe, is normal or normotensive and 
is classified as having consistent BP readings of 120/80 mmHG or below. 
Prehypertensive individuals have repeated BP readings of 121/81-139/89 mmHg, Stage 1 
EH is characterized by BP readings of 140/90-159/99 mmHg, and Stage 2 EH features 
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consistent BP readings of 160/100 mmHg or greater (Kaplan & Victor, 2009) and is of 
immediate concern for intervention (Tobin et al., 2005).  
The prevalence of EH increases with age (Figure 1) for both males and females 
from all ethnicities (Gupta, Gupta, & Pednekar, 2004). Individuals with high BP are also 
more likely to have other CVD risk factors like high cholesterol levels and larger waist 
circumferences (Doris, 2002). By knowing what causes EH, appropriate precautions, 
treatments, therapies, and studies may be developed to combat controllable aspects 
associated with CVD. 
 
Figure 1: Worldwide prevalence of EH by age and subtype between males and females. 
Solid=prehypertensive, checkered=Stage I, hashed=Stage II. (Modified from Gupta et al., 
2004). 
 Unmanaged EH is correlated with CVD severity. Individuals who have been 
diagnosed with EH require treatment for the remainder of their lives to prevent CVD 
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from occurring or advancing (Mathers & Loncar, 2006). Treatment and proper diagnosis 
of EH is critical to prevent or delay health complications. Untreated EH is dangerous as 
left ventricular hypertrophy (LVH) can occur. LVH serves as a marker for enlargement of 
the left ventricle of the heart and can lead to death. This contractile overcompensation by 
the heart leads to damage in the heart, brain, and kidneys of patients with EH (Bauml & 
Underwood, 2010) and elevates the risk of premature death (Katholi & Couri, 2011).  
 EH has a well-known familial aggregation and has been calculated to be 
approximately 40% genetically determined (Deng, 2007). Among people younger than 50 
years, EH occurs 3.8 times more often in those with two or more immediate relatives that 
developed high BP before age 55 (Giner et al., 2000). While many EH cases are 
attributed to genetic factors, there is no single genetic determinate known (Rhodes & 
Bell, 2009). As a result, EH is classified as a polygenic disease.  
Quantitative trait loci (QTL), in addition to genome-wide association techniques, 
have helped in the understanding of EH (Rhodes & Bell, 2009). Three QTLs have been 
shown to contribute to lower BP. Epistatic relationships occur between two of the three 
QTLs (Iigaya et al., 2009). QTL mapping on chromosome 1 of rats revealed hundreds of 
genes linked to regulation of BP (Deng, 2007). For example, the cofactor that regulates 
angiotensin and angiotensinogen receptors, Arrb1, also regulates internalization of the β-
adrenergic receptors (Iigaya et al., 2009). This is linked to BP variations due to the 
products of Arrb1 altering signaling pathways throughout the body. The pathways 
responsible for regulation of BP are included in those influenced by Arrb1 (DeFea, 2008). 
By identifying the genetic targets responsible for BP conditions such as EH, specific 
therapeutics can be developed to treat and diagnose patients. 
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Kasigau, Kenya demographics 
This study is based in Kenya, a developing country of East Africa, with a 
population of 39 million people (Hendriks et al., 2012). There are on average 15 doctors 
per 100,000 people within the country. This is drastically different than that of the 
developed world because there are an estimated 270 doctors per 100,000 people in the 
United States (World Health Organization, 2011). Through Western Kentucky 
University’s Partners In Caring: Medicine in Kenya (PiC:MiK) program, a partnership 
between the people of Kasigau, Kenya and Western Kentucky University, the healthcare 
concerns of Kasigau are addressed. Medical care and education are among the primary 
goals of this initiative and attempt to bridge the disparity in healthcare. This thesis is a 
component of the research focused around the cardiovascular health of the Kasigau 
people. 
Kasigau is located within the Eastern Arc Mountains in sub-Saharan Africa 
between the Taita Hills and Indian Ocean. Within this location, there are scarce resources, 
inadequate healthcare, and diagnosis, treatment, and prevention of EH and other CVD 
specifically are inadequate. These all contribute to negative healthcare consequences for 
the residents of Kasigau. Mount Kasigau, which is part of the Taita Hills, is surrounded 
by the villages of Jora, Makwasinyi, Ngambenyi, Rukanga, Bungule, and Kiteghe. There 
is an additional village included in this study as well. Bughuta is located further away 
from the Taita Hills and does not surround Mount Kasigau directly; however, the village 
is only a few kilometers drive from the other villages of this study. Collectively, all seven 
villages are divided into three sublocations (Bughuta, Rukanga, and Makwasinyi) based 
upon proximity. 
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Preliminary studies have found that in a pilot group (n=159) of individuals, ~67% 
of the Kasigau population has EH. Unlike in developed populations, risk factors such as 
body mass index and cholesterol did not correlate to the prevalence of EH in this 
population (Williams, 2012). Therefore, this preliminary epidemiological work supports 
the hypothesis that genetic or behavioral risk factors may greatly contribute to the 
observed prevalence of EH in Kasigau.  
Burden of CVD  
There are 970 million people worldwide living with EH (Edwards et al., 2000). 
The majority of these, 640 million, live in the developing world. According to the World 
Health Organization (WHO), it is estimated that by 2025 people living with EH will grow 
to 1.56 billion worldwide (Addo, Smeeth, & Leon, 2007). CVDs, primarily due to stroke 
and coronary heart disease, are the leading cause of death globally (Pickering, 1965) and 
account for 30% of all deaths (Miranda, Kinra, Casas, Smith, & Ebrahim, 2008). Deaths 
from CVD are expected to grow 17% overall, with the largest increase, 27%, predicted in 
Africa (Addo et al., 2007).  
The WHO reports that low- to middle- income countries are disproportionately 
affected by CVD with over 80% of all CVD deaths occurring in such areas (Dongfeng et 
al., 2010). People of African descent are particularly vulnerable to EH compared to other 
ethnicities due to both socioeconomic factors and genetics. Many people in Africa are not 
even aware they are hypertensive (Figure 2) because of the lack of preventative care and 
awareness surrounding CVD (Hendriks et al., 2012). 
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Figure 2: Awareness, treatment, and BP control in Kenyan patients with hypertension 
(Modified from Hendriks et al., 2012). 
Recent research has attributed 20% of all deaths in sub-Saharan Africa to 
noncommunicable disease. The term noncommunicable disease is used interchangeably 
with chronic disease and refers to mental illnesses, diabetes, chronic respiratory diseases, 
cancers, CVD, and injuries. Globally, CVD, cancer, and injuries consistently rank as the 
top three conditions in low to low-middle income countries (Miranda et al., 2008). 
The heightened susceptibility of people in low- to middle- income countries, like 
Kenya, to developing EH has three reasons. People in these countries are more exposed 
to risk factors that are known to lead to CVD and other noncommunicable diseases; 
people do not have access to prevention programs compared to people in high- income 
countries; and people do not receive effective and equitable healthcare services because 
the area lacks availability. Early detection services, which are essential to lessening the 
rate of CVD in these countries, are the most effective healthcare service (Hendricks et al., 
2012). Among risk factors, high salt diets and limited access to resources like clean 
drinking water contribute to elevated rates of CVD (Mathers & Loncar, 2006). The 
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poorest people are affected most in any developing country, including Kenya (Jamison et 
al., 2006). 
Approximately half of Kenya’s population (15 million people) are classified as 
very poor and survive on less than 1 USD a day with very limited access to healthcare. 
Awareness of EH within Kenya is essential to effective management of CVD (Figure 2). 
But unfortunately, the necessary treatment for EH is often difficult to obtain for Kasigau 
residents due to the general lack of CVD awareness and low income levels.  
In Kenya, medication for treating EH costs the nation $24 million annually 
(Hendriks et al., 2012). Given that not all EH is effectively controlled pharmaceutically, 
the Kenyan population and economy are left especially vulnerable. For Kenyans that are 
aware they have EH, it is often difficult to afford drugs and/or adjust to the necessary 
lifestyle changes to control and treat their EH. Treatments of cardiovascular conditions 
often include more than a single type of pharmaceutical and/or lifestyle changes 
(Hendricks et al., 2012). Studies have attributed increased CVD rates to the increased 
price of pharmaceutical treatments (Edwards et al., 2000).  
Renin-angiotensin system 
One of the key hormonal systems that regulates and maintains BP and ultimately 
EH development in the body through controlling salt balance and arterial tone is the 
renin-angiotensin system (RAS) (Giner et al., 2000). The RAS pathway is composed of 
renin, angiotensin I-converting enzyme, angiotensinogen, and angiotensin II receptor type 
I, predominately, as well as several other components.  
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Each protein in the pathway is encoded by a separate gene. The genes are 
angiotensin converting enzyme (ACE), angiotensinogen (AGT), renin (REN), and 
angiotensinogen II receptor isoform 1a (AGTR1), respectively (Figure 3). AGT encodes 
the protein angiotensinogen which is cleaved by renin to form angiotensin I. Angiotensin 
I is cleaved by ACE to form angiotensin II, and angiotensin II is responsible for 
stimulating aldosterone secretion (Mills, 2011) that ultimately elevates BP within the 
arteries of multiple organ and tissue systems (Pickering, 1965). Aldosterone is also 
regulated by angiotensinogen II receptor isoform 1a (Mills, 2011) which increases 
intracellular calcium concentration and phosphorylation of proteins (Pickering, 1965). 
 
 
 
 
 
 
Figure 3: Renin-angiotensin system. The arrows indicate the hormonal pathway that leads 
to changes in arterial tone. Angiotensinogen is secreted from the liver, broken down to 
angiotensin I by renin, and further converted into angiotensin II by angiotensin 
converting enzyme. Angiotensin II is responsible for numerous physiological effects 
ultimately resulting in water and salt retention (Public Domain). 
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Single nucleotide polymorphisms 
Genetic polymorphisms are defined as a difference in the DNA sequence among 
individuals, groups, or populations that affect a variety of traits within the organism and 
those in the coding region represent about 90% of the common variation within the 
genome (Doris, 2002). Genetic polymorphisms produce an individual’s distinctive 
behavioral, physical, and social responses to events, environments, and conditions 
throughout their lifetime (Giner et al., 2000). Individuals differ both in appearance and in 
their genetic makeup because of polymorphic variations; however, polymorphisms also 
have implications in disease susceptibility (Doris, 2002). There are numerous 
polymorphisms in RAS genes that have been identified, and several of these correlate 
with EH in Asian and European populations (Tobin et al., 2005).  
The most stable variation in the human genome is in the form of a single 
nucleotide polymorphism (SNP) (Doris, 2002). It was recently discovered that SNPs are 
not distributed equally over the entire portion of the genome but are instead found 
concentrated within noncoding regions of DNA (Murray, Granner, Mayes, & Rodwell, 
2000). Several SNPs in RAS genes have previously been identified; three were selected 
for this study based upon prior correlation to increased EH susceptibility. The SNPS 
included in this study are: AGT M235T, hydroxysteroid dehydrogenase 11β2 G534A 
(HSD11β2), and the AGTR1 A1166C.  
 When polymorphisms are identified, they are provided a reference SNP ID (rs) 
number. An rs number is defined as a variation at a location on an ideal reference 
chromosome and archived in the Single Nucleotide Polymorphism Database (dbSNP), a 
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free public archive of genetic variation within and among species. The database was 
developed and is hosted by the National Center for Biotechnology Information (NCBI) of 
the National Institutes of Health (NIH). The rs number and the associated allelic variants 
examined in this study are rs699 (AGT M235T), rs5186 (AGTR1 A1166C), and rs5479 
(HSD11β2 G534A). 
Angiotensinogen 
 Prior studies have shown that the M235T missense polymorphism (rs699) of AGT 
directly mediates a predisposition for EH (Ortlepp et al., 2003). The thymine allele, 
which codes for methionine, is the normal variant of AGT; higher angiotensinogen levels 
are caused by the C allele via inability of angiotensinogen to be cleaved correctly by 
renin, which encodes for threonine. For clarification in this thesis, thymine will be 
abbreviated T. The susceptible cytosine allele is known to lead to higher BP and 
increased risk for cardiovascular conditions (Ortlepp et al., 2003). Genotypes are 
classified as C/C, T/T, or C/T based on the presence of alleles. 
 Ethnicity also seems to be a key factor with regard to how the amino acid 
substitution influences EH (Dongfeng et al., 2010). Asian and white European individuals 
are more likely to have EH based upon this amino acid of T to C substitution. The C 
allele compared to those without the variant caused improper BP regulation and end-
organ damage (Ortlepp et al., 2003). This was especially true from individuals with 
family histories of EH, although familial polymorphism rates were not discussed (Poch et 
al., 2001). Notably absent from current literature on EH is the relation between the rs699 
polymorphism and EH in East African populations. 
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Angiotensin II receptor, isoform 1 
 There are many variants in AGTR1, each of which impact BP (Bonnardeaux et al., 
1994). The role of the AGTR1 gene product is to balance the narrowing of blood vessels 
and aldosterone secretion by binding angiotensin II (Murphy, Alexander, Griendling, 
Runge, & Bernstein, 1991). Within the body, it has also been shown to trigger 
inflammation by inducing oxidative stress through increasing sensitivity to inflammatory 
mediators. 
 Further analysis is required on the specific variants of AGTR1 in order to properly 
gauge their influence on cardiovascular conditions like EH. Due to it’s predisposition to 
EH susceptibility, the A-to-C variant (rs5186) in the 3’ end of the gene that codes the 
receptor at nucleotide 1166 was linked to a high frequency of elevated BP in white 
subjects (Amir et al., 2009). This linkage has been essential to proper understanding of 
the global understanding of AGTR1’s contributions to EH.  
 The AGTR1 A allele is identified as the normal variant, while the C allele has been 
classified as the susceptible variant for EH. Genotypes are classified as A/A, A/C, or C/C. 
In a study of Japanese populations with severe EH, the frequency of C/C and A/C 
genotypes is increased in patients with EH compared to normotensive controls (Poch et 
al., 2001). The genotype C/C for rs5186 is rare (5%) in African American populations 
because it is attributed to an increased global mortality due to premature heart failure 
(Bonnardeaux et al., 1994). There is little research being performed on the polymorphic 
variations within AGTR1, especially in populations from East Africa.  
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Hydroxysteroid (11-beta) dehydrogenase 
 The level and activity of the hormone cortisol is determined by HSD11β2 (Persu, 
2005). Cortisol production is elevated in stress conditions and mediates the increased 
recruitment of fat distribution to stressed areas of the human body (Rhodes & Bell, 2009). 
HSD11β2 is a microsomal short-chain dehydrogenase that catalyzes the reduction of 
organic compounds. Within the body, it is responsible for converting the active hormone 
cortisol to the inactive form cortisone. The amino acid change in the HSD11β2 C534A 
(rs5479) polymorphism is essential in the hormone conversion of the active version 
cortisol to inactive cortisone (Persu, 2005). HSD11β2 also plays a key role in sodium 
homeostasis through mediating the absorption and release of sodium by inhibiting the 
mineralocorticoid receptor. Compromised function results in overstimulation of receptors 
by cortisol leading to sodium retention, hypokalemia, and ultimately EH (Wilson et al., 
1998 & Carvajal et al., 2005). Normally, HSD11β2 regulates excess aldosterone 
secretions, however, in an individual with EH, this mechanism is altered or completely 
shut down so that secretions are able to accumulate. These secretions make it difficult for 
BP to be maintained. Studies have found that the HSD11β2 rs5479 SNP causes increased 
BP (Mune, Rogerson, Nikkilä, Agarwal, & White, 1995). This mutation also causes 
overcompensation of potentially hazardous elements, such as sodium, being retained 
within the body. The colon, which are part of the human digestive system, and kidneys, 
an integral component of the body’s urinary system, are primarily affected by these 
changes in allele frequency. 
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Goals of research 
The goal of this research project was to evaluate the prevalence of three SNPs that 
had in previous studies and ethnicities been correlated to an increased risk for EH within 
Kasigau, Kenya. This was achieved by performing allelic discriminations and calculating 
allelic and genotype frequencies of rs699, rs5479, and rs5186 in individuals from each of 
the rural Kasigau villages. Subsequently, allelic genotype frequency allowed for 
associations of the RAS SNPs to normotensive, prehypertensive, Stage I hypertensive, 
and Stage II hypertensive BP responses and determination of Hardy-Weinberg 
equilibrium (HWE). This work serves as a model study examining the variation of 
polymorphic changes in a rural East African population with a high amount of EH 
(Williams, 2012). Overall, this work evaluated how polymorphic variation in RAS genes 
correlate to phenotypic differences of EH in Kasigau, Kenya. 
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MATERIALS AND METHODS 
Compliance/informed consent 
This study was approved by Western Kentucky University's Human Subjects 
Review Board (HR-174, Appendix A) and the Taita District Health Officer in Kenya 
(Appendix B). All participants were read an informed consent document and their 
voluntary willingness to participate in the study implied their consent (Appendix C). 
Participants were also modestly compensated financially for participation. 
Study participants 
Participants for this study were selected based upon a cross-sectional population 
assessment of the Kasigau, Kenya area villages (Jora, Rukanga, Makwasinyi, Bungule, 
Kiteghe, and Bughuta) using census data of the region. The area was subdivided into 
sublocations: Rukanga, Makwasinyi, and Bughuta which compromise 29%, 21%, and 
50% of the total population, respectively. Sublocations consisted of one to four distinct 
villages. 
Participant criteria also included being 45-75 years of age since the onset of EH 
occurs primarily in older people. Stratification of participants by sex from the census data 
was also essential for the overall population structure to match any differences among 
villages. The recruitment goal was 50% males and 50% nonpregnant females of Kasigau, 
although actually 66% of participants were females and 34% were males (Table 1). 
Overall, 400 individuals were recruited to take part in the study, although only 161 
individuals eventually participated in the study. 
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Table 1: Demographics of Kasigau. Total population of Kasigau and number of 
individuals per sublocation.  
  Total 
Population 
Pilot 
Study 
        
Demographics n % n % Female % Males % 
Kasigau 13,696  161  107 66% 54 34% 
Rukanga 3,940 29% 63 39% 47 75% 16 25% 
Makwasinyi 2,847 21% 31 19% 12 39% 19 61% 
Bughuta 6,909 50% 67 42% 48 72% 19 28% 
 
Buccal cell acquisition 
Buccal cells were acquired from participants using Isohelix DNA Buccal Cell 
Swabs (Cell Projects Ltd., Kent, UK; Cat. No: SK-2S). These individually wrapped 
swabs were advantageous because they could yield up to 5 μg of human genomic DNA 
and were sealed to avoid contamination. Swabs were labeled by village and participant 
number in order to correlate genotype data to an individual’s demographic data. 
Swabbing occurred during the participant’s clinic visit time and involved the 
thorough swabbing of the inside of the cheek for one minute. After acquisition of buccal 
cells, samples were sealed and allowed to dry. Upon arrival in the United States, the 
samples were stored at 4°C prior to genomic DNA isolation. 
Genomic DNA isolation 
Genomic DNA was isolated from swabs by standard alkaline lysis using the 
QIAamp DNA Mini Kit (Qiagen; Valencia, CA, USA; Cat. No: 51306). The results from 
the kit and swabs provided 500-2000 ng of DNA per sample while rapidly purifying and 
creating high quality, ready-to-use DNA. Groups of 24 samples were processed per 
extraction cycle. 
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To isolate DNA, the swabs were submerged in 1X phosphate buffer saline (PBS). 
Upon being exposed to PBS, protease K and buffer AL were added to each sample 
according to kit protocol. Protease K was used as the optimal enzyme with the lysis 
buffer (Qiagen; Valencia, CA, USA). Samples were immediately capped and vortexed 
briefly after addition of buffer AL. A dry water bath (56°C, 10 min) was used for 
activation of the protease within each sample. Ethanol (96-100%) was then added to the 
contents of the sample. Brief vortexing and centrifugation of capped sample tubes 
followed.  
The samples were applied to a spin column from the QIAamp DNA Mini Kit and 
centrifuged at 8,000 rpm for one minute to isolate genomic DNA. Filtrates were 
discarded. The columns were then washed with a series of wash buffers provided in the 
kit followed by centrifugation. DNA was eluted from the spin column by the addition of 
buffer AE followed by centrifugation (8,000 rpm, 1 min) to complete isolation. 
Sample DNA was stored at -20°C. This storage technique was recommended for 
long-term storage (Qiagen; Valencia, CA, USA). It also maintained the quality of the 
DNA with minimal degradation. All genomic DNA was isolated from samples prior to 
quantification. 
Nanodrop analysis 
DNA concentrations and purity were determined by the ratio of absorbance of UV 
light at 260/280 nm using a Nanodrop spectrophotometer (Thermo Scientific; 
Wilmington, DE, USA). Two µl of each sample was analyzed to determine final DNA 
concentration. Typically, a buccal swab would yield 3-23 ng/µl of genomic DNA. 
Although variable, 96% of Kasigau genomic DNA samples were measured within this 
concentration range. 
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Allelic discrimination analysis  
Real-time Polymerase Chain Reaction (RT-PCR) was used for genotype and 
allelic discrimination purposes. The TaqMan SNP Genotyping Assays Protocol (Applied 
Biosystems; Foster City, CA, USA) was used for allelic discrimination in this study. 
These assays use fluorescent dyes as reporters of DNA binding. Each dye is covalently 
attached to each primer used in the PCR reaction and includes a blue dye, called FAM, 
and a green dye, called VIC. A reference dye, ROX, was also used. Either blue or green 
coloration were identified through the use of Sequence Detection System (SDS) software 
(Applied Biosystems; Foster City, CA, USA). Both a reporter dye, which is detected by 
SDS, and a quencher, used for binding to DNA, are contained on the 5’ and 3’ end of the 
assay, respectively (Figure 4).  
 
Figure 4: TaqMan® genotyping assay. (“TaqMan® Genotyping Assay Product Bulletin,” 
Applied Biosystems; Foster City, CA, USA). 
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All samples were run in triplicate on a MicroAmp® Optical 96-well reaction plate 
(Applied Biosystems; Foster City, CA, USA) in an Applied Biosystems Prism 7300 Real-
Time polymerase chain reaction instrument. Both positive controls and negative controls, 
without DNA template, were also included. Triplicate sampling reduces the likelihood of 
bias or error. The PCR exploits the 5’ nuclease activity of AmpliTaq Gold® DNA 
Polymerase (Applied Biosystems; Foster City, CA, USA) to cleave the assay during the 
reaction. This cleavage is responsible for separating the assay’s quencher and reporter 
dyes from one another for PCR. By cleaving the assay into such parts, the color intensity 
of the reporter dye increases in fluorescence. The fluorescence is only successful if the 
target sequence within the genomic DNA is complementary to that of the cleaved assay 
sequence. If not cleaved, the reporter and quencher dye remain too close to one another, 
and Forster-type energy transfer takes effect between the two dyes. The 3’ end of the 
assay is blocked so that polymerization of the assay can be completed during PCR. No 
extension of the assay occurs during PCR (Figure 4). 
For each sample, following quantification of DNA, water and DNA (in µL) were 
added to each well so the final volume per well totaled 11.25 µL with a final 
concentration of 20 ng of DNA per well. Initial DNA concentrations ranged from 1.42-
11.87 ng/µL. Next, a premade master mix was added to each well along with the SNP 
assay. The master mix contained the following: 50 nM of forward primer labeled with 
VIC dye, 50 nM of reverse primer labeled with FAM dye, deoxyribonucleotides with 
deoxyuridine triphosphates, AmpliTaq Gold DNA polymerase, AmpErase® uracil-N-
glycosylase, optimized buffer, and passive reference components. The primer pair 
sequence for each SNP is provided in Table 2. 
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Table 2: RAS SNP primer sequences. The context sequence is exclusive to the SNP, while 
the forward and reverse primers are in reference to the surrounding genetic code. Each 
context sequence has portions identical to the primers. 
SNP Context sequence Reverse primer (3’ → 5’) Forward primer (5’ → 3’) 
 
rs699 
CAGGGTGCTGTCCACACT
GGCTCCC[A/G]TCAGGGA
GCAGCCAGTCTTCCATCC 
ACGTTGGATGAAAC
GGCTGCTTCAGGTGC 
ACGTTGGATGTGATAG
CCAGGCCCAGCT 
rs5186 
TGCAGCACTTCACTACCA
AATGAGC[A/C]TTAGCTAC
TTTTCAGAATTGAAGGA 
AGAAAAGTCGG
TTCAGTCCAC 
CCCCAAAAGCCAAATC
CCAC 
rs5479 
TGCTAGAGTTCACCAAGG
CCCACAC[A/C]ACCAGCAC
CGGTCAGTGGCAAGTGT 
ACCAGCACCGGTCA
GTGGCAAGTGT 
TGCTAGAGTTCACCAA
GGCCCACAC 
 
The following were used as cycling conditions: activation (95°C-10 minutes); 
denaturing (92°C-15 seconds); extending and annealing (60°C- 70 seconds). The cycling 
procedure was repeated 50 times. This was performed to sufficiently elevate the 
fluorescence for SDS to detect within each well.  
A final postrun was performed on the plate after PCR cycling.  The postrun step 
(60°C-l minute) occurred for all 96 wells. This was done in comparison to the prerun of 
the plate to detect changes in fluorescence.   
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Statistical analysis  
The Hardy-Weinberg Equilibrium (HWE) equation (Figure 5) was used to 
compare the actual genetic composition for this study’s participants to a hypothetical 
gene structure, probabilities of frequencies and expected values of alleles were derived 
from observed data and analyzed using the equation for HWE. The HWE equation 
includes the genotype frequency that is composed of either or both the dominant ‘A’ 
and/or recessive ‘a’ allele. The ‘A’ allele is known as the common allele, while the ‘a’ 
allele is deemed the rare allele. The frequencies of the genotypes associated with these 
alleles allow for further statistical analysis to be performed.  
p2+2pq+q2=1 
Figure 5: HWE equation. p2=frequency of genotype AA, p=frequency of allele A, 
q2=frequency of genotype aa, q=frequency of allele a (Public Domain). 
 
 Genotype frequencies were analyzed in this study using a Pearson’s Chi Square 
test. The equation is used to determine significance of deviations in frequencies and 
HWE models (Figure 6). This calculation was used to compare genotype distributions of 
SNPs within different EH classifications for all individual sublocations. The genotype 
distributions for rs699, rs5186, and rs5479 were also calculated for the total Kasigau 
population.  
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Figure 6: Pearson’s Chi-Square equation. e=expected, o=observed (Public Domain). 
 
Statistical analysis was performed using a Pearson’s Chi Square test in R (R 
Development Core Team, 2008). Probability values are reflections of the area under the 
curve of Gaussian distribution (bell curve) of genotypes and are reported as p-values in 
the resulting tables.  In order to investigate whether the distribution of each SNP’s 
genotype differed from one another, a Chi square value was calculated. 
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RESULTS 
Prior to allelic discrimination, the concentration and purity of DNA isolated from 
all buccal cells was determined. All Nanodrop 260/280 ratio concentrations and purities 
were 1.7-1.9 and considered to be pure DNA. This step was done to assure that the 
contents of the isolation were DNA and not protein. Ratios of 1.8 are considered pure 
DNA. There is a 2.0 approximation ratio that defines pure RNA. A ratio that is 
approximately 0.6 is referred to as pure protein (Nanodrop, 2007). This is critical for 
genotype and allelic studies to be performed. If there were high protein or RNA 
contaminants, the allelic discrimination, polymerase chain reaction efficiency, and 
genotype determinations would be difficult and inaccurate. 
 
Allele and genotype frequency of the AGT rs699 SNP correlated with EH 
classification 
There is predisposition to EH for individuals who carry the variant C allele of the 
rs699 SNP. As a whole for AGT rs699, approximately 0.80 of the Kasigau population 
possesses the C allele, while only approximately 0.20 possess the T allele (Figure 7). This 
allele distribution was also observed in all three sublocations. When the derived allelic 
frequency was subsequently assessed as genotype, Kasigau displayed 0.63 C/C, 0.34 C/T, 
and 0.03 T/T (Figure 8). The sublocations differed, however, in genotype distribution; 
Makwasyini and Rukanga had a C/T of ~0.23; however, Bughuta had an equal 
distribution of C/T and C/C genotypes. When the observed genotypes were compared 
with the expected frequencies predicted by HWE, Kasigau, Rukanga, and Makwasinyi 
exhibited a nonsignificant difference, p= 0.34, 0.14, 0.64, respectively whereas the 
Bughuta AGT rs699 genotype frequencies deviated from HWE (p ≤ 0.001) (Figure 8).  
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To assess whether allelic frequency varied based upon the severity of EH, the 
derived allelic and genotypic distributions of rs699 were determined for normotensive, 
prehypertensive, Stage I EH, and Stage II EH, both for the total Kasigau population, and 
for the three sublocations. EH classifications were based upon the systolic BP of 
participants (systolic values only will be used throughout the results). Regardless of 
sublocation, for AGT rs699 there were more C alleles than T alleles for all EH 
classifications (Table 3). The T allele frequency for Kasigau ranged from 0.15-0.23, while 
the C allele frequency ranged from 0.77-0.85 across all four EH classifications. With 
regard to genotype, the majority of participant genotypes for rs699 were C/C. When the 
obtained genotype frequencies of AGT rs699 in each EH category were compared with 
the expected frequencies predicted by HWE, the polymorphism exhibited a 
nonsignificant difference for all EH categories (Χ2 < 3.84 with one degree of freedom). 
The exception to this was prehypertensive individuals from Rukanga (Χ2= 5.4, p ≤ 0.01) 
(Table 3).  
Based upon these results, the majority of people in Kasigau possess the 
susceptible allele of the AGT rs699 SNP. While this may be a partial contributor to the 
high prevalence of EH observed, there is no statistical difference between the frequency 
of the allele in normotensive versus hypertensive Kasigau participants. More statistical 
analysis will need to be conducted to confirm these results. In Bughuta, the fact that the 
genotype frequencies for this SNP did not demonstrate HWE suggests that non-random 
mating may contribute to this selective pressure as evidenced by traditional village 
customs.  
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Figure 7: AGT rs699 allele frequencies for Kasigau. n= the number of alleles present in 
each sublocation. 
 
 
Figure 8: AGT rs699 genotype distribution for Kasigau. n= the total number of 
participants in each sublocation. Hardy-Weinberg equilibrium was tested using the Χ2 
test. *= p ≤ 0.05.  
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Table 3: AGT rs699 genotype distribution and allele frequencies per EH classification in 
Kasigau. HWE, Hardy-Weinberg equilibrium. *= p ≤ 0.05. 
Rukanga Genotype Normotensive Prehypertensive Type I EH Type II EH 
 T / T 1 1 0  2 
 T /C 2 1 5 8 
 C/C 11 14 13 18 
 HWE X2= 2.44 
p= 0.12 
X2= 5.4 
p= 0.01* 
X2= 0.47 
p= 0.49 
X2= 0.68 
p= 0.42 
 Allele Normotensive Prehypertensive Type I EH Type II EH 
 T 4 3 5 12 
 C 24 29 31 44 
 f (T) 
f (C) 
0.14 
0.86 
0.09 
0.91 
0.14 
0.86 
0.21 
0.79 
Makwasinyi Genotype Normotensive Prehypertensive Type I EH Type II EH 
 T / T 0 0 0 1 
 T /C 0 2 3 2 
 C/C 1 9 4 8 
 HWE X2= N/A 
p= N/A 
X2= 0.14 
p= 0.74 
X2= 0.58 
p= 0.47  
X2= 1.93 
p= 0.20 
 Allele Normotensive Prehypertensive Type I EH Type II EH 
 T 0 2 3 4 
 C 2 20 11 18 
 f (T) 
f (C) 
0.00 
1.00 
0.09 
0.91 
0.21 
0.79 
0.18 
0.82 
Bughuta Genotype Normotensive Prehypertensive Type I EH Type II EH 
 T / T 0 0 0 0 
 T /C 9 9 10 9 
 C/C 9 11 14 9 
 HWE X2= 2.26 
p= 0.16 
X2= 1.65 
p= 0.19 
X2= 1.59 
p= 0.20 
X2= 2.26 
p= 0.16 
 Allele Normotensive Prehypertensive Type I EH Type II EH 
 T 9 10 9 8 
 C 27 38 31 14 
 f (T) 
f (C) 
0.25 
0.75 
0.21 
0.79 
0.23 
0.78 
0.36 
0.64 
Kasigau Genotype Normotensive Prehypertensive Type I EH Type II EH 
 T/T 1 1 0 3 
 T/C 12 14 17 18 
 C/C 17 38 28 30 
 HWE X2= 0.60 
p= 0.52 
X2= 0.05 
p= 0.82 
X2= 2.5 
p= 0.12 
X2= 0.02 
p= 0.89 
 Allele Normotensive Prehypertensive Type I EH Type II EH 
 T 14 16 17 24 
 C 46 90 73 78 
 f (T) 
f (C) 
0.23 
0.77 
0.15 
0.85 
0.19 
0.81 
0.23 
0.77 
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Allele and genotype frequency of the AGTR1 rs5186 SNP correlated with EH 
classification 
The C allele of AGTR1 rs5186 has been shown to be correlated with elevated BP 
(Gillespie et al., 2005). When the Kasigau population was evaluated for this variant, only 
0.02 possessed the C allele while 0.98 had the A allele (Figure 9). This allelic distribution 
was essentially the same in all three sublocations. When allelic distribution was evaluated 
as genotype frequency for rs5186, Kasigau displayed 0.96 A/A, 0.04 A/C, and 0.00 C/C 
(Figure 10). This was not unexpected since the C/C genotype is known to cause 
premature heart failure (Amir et al., 2009). The only C alleles for AGTR1 rs5186 were 
identified in heterozygous participants. There was no significant difference in genotypic 
distribution for rs5186 among sublocations. Moreover, when the observed genotypes 
were compared with the expected frequencies predicted by HWE, all locations exhibited 
a nonsignificant difference, p= 0.82, 0.86, 0.93, and 0.91, respectively for Kasigau, 
Rukanga, Makwasinyi, and Bughuta (Figure 10). 
 
 
 
 
 
 
 
 
Figure 9: AGTR1 rs5186 allele frequencies for Kasigau. n= the number of alleles present 
in each sublocation.  
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To assess whether allele frequency and genotype varied based upon severity of 
EH, the derived allelic and genotypic distributions of AGTR1 rs5186 were determined for 
normotensive, prehypertensive, Stage I EH, and Stage II EH individuals for the total 
Kasigau population and for the individual sublocations. For AGTR1 rs5186, there was a 
higher frequency of A alleles than C alleles across all EH classifications and locations 
(Figure 9). The A allele frequency in Kasigau as a whole ranged from 0.97-0.99 for all 
EH classifications, while the C allele frequency ranged from 0.01-0.03 (Table 4). 
When the derived genotype frequencies of the AGTR1 rs5186 SNP in each EH 
category were compared with the expected frequencies predicted by HWE, the 
polymorphism demonstrated nonsignificant differences for all locations across all EH 
phenotypes (Χ2 < 3.84 with one degree of freedom) (Table 4). It should be noted that 
HWE could not be determined for many of the prehypertensive, Stage I, and Stage II 
groups. This is to be expected since the C allele is not highly represented in this small 
sample size and moreover since a known selection exists against the C/C genotype.  
 
 
 
 
 
 
 
 
Figure 10: AGTR1 rs5186 genotype distribution for Kasigau. n= the total number of 
participants. Hardy-Weinberg equilibrium was tested using the Χ2 test.  
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Table 4: AGTR1 rs5186 genotype distribution and allele frequencies per EH classification 
in Kasigau. HWE, Hardy-Weinberg equilibrium. 
Rukanga Genotype Normotensive Prehypertensive Type I EH Type II EH 
 A/A 10 18 18 29 
 A/C 1 0 0 2 
 C/C 0 0 0 0 
 HWE X2= 0.03 
p= 0.87 
X2= N/A 
p= N/A 
X2= N/A 
p= N/A 
X2= 0.05 
p= 0.85 
 Allele Normotensive Prehypertensive Type I EH Type II EH 
 A 21 36 36 60 
 C 1 0 0 2 
 f (A) 
f (C) 
0.95 
0.05 
1.00 
0.00 
1.00 
0.00 
0.97 
0.03 
Makwasinyi Genotype Normotensive Prehypertensive Type I EH Type II EH 
 A/A 2 10 7 11 
 A/C 0 1 0 0 
 C/C 0 0 0 0 
 HWE X2= N/A 
p= N/A 
X2= 0.11 
p= 0.87 
X2= N/A 
p= N/A  
X2= N/A 
p= N/A 
 Allele Normotensive Prehypertensive Type I EH Type II EH 
 A 4 21 14 22 
 C 0 1 0 0 
 f (A) 
f (C) 
1.00 
0.00 
0.95 
0.05 
1.00 
0.00 
1.00 
0.00 
Bughuta Genotype Normotensive Prehypertensive Type I EH Type II EH 
 A/A 27 24 20 10 
 A/C 1 0 0 1 
 C/C 0 0 0 0 
 HWE X2= 0.04 
p= 0.92 
X2= N/A 
p= N/A 
X2= N/A 
p= N/A 
X2= 0.04 
p= 0.87 
 Allele Normotensive Prehypertensive Type I EH Type II EH 
 A 35 48 40 21 
 C 1 0 0 1 
 f (A) 
f (C) 
0.97 
0.03 
1.00 
0.00 
1.00 
0.00 
0.95 
0.05 
Kasigau Genotype Normotensive Prehypertensive Type I EH Type II EH 
 A/A 33 50 44 47 
 A/C 2 1 0 3 
 C/C 0 0 0 0 
 HWE X2= 0.39 
p= 0.86 
X2= 0.05 
p= 0.94 
X2= N/A 
p= N/A 
X2= 0.05 
p= 0.83 
 Allele Normotensive Prehypertensive Type I EH Type II EH 
 A 68 101 88 97 
 C 2 1 0 3 
 f (A) 
f (C) 
0.97 
0.03 
0.99 
0.01 
1.00 
0.00 
0.97 
0.03 
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Allele and genotype frequency of the HSD11β2 rs5479 SNP correlated with EH 
classification 
The HSD11β2 gene product is responsible for inactivation of cortisol by 
converting it to cortisone. When the kidney variant, HSD11β2, is abundant, cortisol levels 
increase resulting in salt and water reabsorption leading to increases in BP. Previously, 
the A allele in HSD11β2 rs5479 SNP has been identified as a salt sensitive genetic variant 
(Dongfeng, 2010). In Kasigau, 0.69 of the population possess the C variant of HSD11β2, 
while 0.31 carry the A allele (Figure 11). Allelic frequency was further assessed as 
genotype for rs5479; Kasigau displayed 0.46 C/C, 0.46 A/C, and 0.08 A/A (Figure 12). 
Moreover, when the observed genotypes were compared with the expected frequencies 
predicted by HWE, all locations exhibited a nonsignificant difference, p= 0.33, 0.23, 
0.78, and 0.87, respectively for Kasigau, Rukanga, Makwasinyi, and Bughuta (Figure 
12). 
To assess whether allelic frequency varied based upon the severity of EH, the 
derived allelic and genotypic distributions of rs5479 were determined for normotensive, 
prehypertensive, Stage I EH, and Stage II EH, both for the total Kasigau population, and 
for the three sublocations. Regardless of sublocation, for HSD11β2 rs5479 there were 
more C alleles than A alleles across all EH classifications (Table 5). The A allele 
frequency for Kasigau across all EH classifications ranged from 0.27-0.37, while the C 
allele frequency ranged from 0.63-0.73.  When the obtained genotype frequencies of  
HSD11β2 rs5479 in each EH category were compared with the expected frequencies 
predicted by the HWE, the polymorphism exhibited a nonsignificant (X2 < 3.84 with one 
degree of freedom) difference for all locations across all EH categories. While not above 
the 3.84 value for HWE, both prehypertensive individuals from Rukanga (X2= 3.79, p ≤ 
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0.05) and normotensive participants in Kasigau as a whole (X2= 3.71, p= 0.06) had X2 
values that might suggest, with an increase in sample size, that they are not in 
equilibrium. Interestingly, while odds ratio analyses need to be performed, there is a 
general trend in all locations but Bughuta, that the susceptible A allele increases as 
severity of EH increases. An example of this is that there are more A alleles in 
participants with Stage II EH versus normotensive (Table 5).   
 
 
Figure 11: HSD11β2 rs5479 allele frequencies for Kasigau. n= the number of alleles 
present in each sublocation. 
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Figure 12: HSD11β2 rs5479 genotype distribution for Kasigau. n= the total number of 
participants in each sublocation. Hardy-Weinberg equilibrium was tested using the X2 
test. 
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Table 5: HSD11β2 rs5479 genotype distribution and allele frequencies per EH 
classification in Kasigau. HWE, Hardy-Weinberg equilibrium. *= p ≤ 0.05. 
Rukanga Genotype Normotensive Prehypertensive Type I EH Type II EH 
 A/A 0 0 2 4 
 A/C 6 10 14 10 
 C/C 3 5 8 14 
 HWE X2= 2.27 
p= 0.13 
X2= 3.79 
p= 0.05* 
X2= 1.4 
p= 0.23 
X2= 1.5 
p= 0.34 
 Allele Normotensive Prehypertensive Type I EH Type II EH 
 A 6 10 16 18 
 C 12 20 30 38 
 f (A) 
f (C) 
0.33 
0.67 
0.33 
0.67 
0.35 
0.65 
0.32 
0.68 
Mwakwasinyi Genotype Normotensive Prehypertensive Type I EH Type II EH 
 A/A 0 0 1 2 
 A/C 1 6 4 3 
 C/C 1 5 2 5 
 HWE X2= 0.21 
p= 0.64 
X2= 1.57 
p= 0.21 
X2= 0.15 
p= 0.66 
X2= 1.24 
p= 0.28 
 Allele Normotensive Prehypertensive Type I EH Type II EH 
 A 1 6 6 7 
 C 3 16 8 13 
 f (A) 
f (C) 
0.25 
0.75 
0.27 
0.73 
0.43 
0.57 
0.35 
0.65 
Bughuta Genotype Normotensive Prehypertensive Type I EH Type II EH 
 A/A 0 3 1 1 
 A/C 8 8 9 4 
 C/C 10 12 10 6 
 HWE X2= 1.49 
p= 0.23 
X2= 0.58 
p= 0.39 
X2= 0.37 
p= 0.57 
X2= 0.04 
p= 0.78 
 Allele Normotensive Prehypertensive Type I EH Type II EH 
 A 8 14 11 6 
 C 28 32 29 16 
 f (A) 
f (C) 
0.22 
0.78 
0.30 
0.70 
0.28 
0.72 
0.27 
0.73 
Kasigau Genotype Normotensive Prehypertensive Type I EH Type II EH 
 A/A 0 3 4 7 
 A/C 15 24 25 17 
 C/C 14 22 21 25 
 HWE X2= 3.71 
p= 0.06  
X2= 0.96 
p= 0.28 
X2= 0.92 
p= 0.36 
X2= 2.13 
p= 0.17 
 Allele Normotensive Prehypertensive Type I EH Type II EH 
 A 15 30 33 31 
 C 43 68 67 67 
 f (A) 
f (C) 
0.26 
0.74 
0.31 
0.69 
0.33 
0.67 
0.32 
0.68 
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DISCUSSION 
The allelic and genotype frequencies of three different SNPs of the RAS, known 
to influence predisposition to EH (rs699, rs5479, and rs5186), were evaluated from a 
population of individuals living in the rural villages of Kasigau, Kenya. The allele 
frequencies were compared across normotensive, prehypertensive, Stage I hypertensive, 
and Stage II hypertensive BP responses from the same individuals.  Additionally, the 
genotype distribution in each classification was evaluated for HWE. Overall, this work 
begins to investigate how polymorphic variation in RAS genes influence phenotypic 
differences of EH in Kasigau, Kenya.  
Most of the genotype frequencies for all three SNPs were in HWE when 
evaluated based upon EH classification; this is consistent with other studies as well 
(Rhodes & Bell, 2009). One exception to the observed HWE was the genotype frequency 
of the rs699 SNP in participants from Bughuta. Additionally, prehypertensive participants 
from Rukanga are not in HWE of rs699 according to this study.  
The most significant finding of this study was that most of the participants 
possessed the susceptible rs699 variant. To our knowledge, this is the first report to 
identify a high prevalence of this susceptible allele in a cohort of East African 
participants. The current study also discovered a geographical difference of the frequency 
of the alleles in Kasigau. Tribal differences may possibly be contributing to this 
observation since the sublocation of Bughuta has the most non-Taita persons residing 
there (Williams, 2012). 
The AGT rs699 SNP may be contributing to the severity of EH observed in this 
study. The ancestral T allele, which codes for methionine, encodes AGT at a normal rate. 
Meanwhile, the susceptible variant is responsible for inappropriate amounts of the 
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angiotensinogen protein being produced. The amount of protein within the body can vary 
depending upon other, nongenetic factors. Excess or deficiencies of the angiotensinogen 
protein has been shown to have detrimental clinical effects that expand beyond, yet 
include EH and other CVD (Deng, 2007). Therefore, the amount of angiotensinogen 
within the majority of Kasigau people is likely altered, which can influence the rate, 
acquisition, and stage of EH. This study found that in all three sublocations, the T allele 
frequency was greatest in either Stage I or Stage II EH participants. 
While previous studies indicate a high prevalence of EH in Kasigau, it may 
conceivably be even higher (Williams, 2012). It is possible that many Kasigau 
individuals with the most severe forms of EH (Stage II EH) were unable to participate in 
this study because of their poor health due to cardiovascular complications and disease. 
This is especially true because premature death is also a suspected effect caused by the 
rs699 susceptible C allele variant (Giner et al., 2000), something that is particularly 
concerning based upon the results of this study. The majority of participants possessed at 
least one C allele.  
Globally, CVD and EH increase in populations as susceptible variant alleles 
increase in frequency (Mills, 2011). In this study, there is a slight increase throughout 
Kasigau in EH prevalence for heterozygote carriers of the susceptible allele of rs699. 
However, in Kasigau, those with the homozygous ancestral allele condition of rs699 were 
primarily normotensive.  
The A allele is the predominant allele for AGTR1 in this population. This finding 
though can be attributed to the rare occurrence of the C allele of AGTR1 found globally 
(Amir et al., 2009). Previous research has shown that the presence of the susceptible C 
allele in AGTR1 correlates with increased severity of cardiovascular conditions (Poch et 
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al., 2001). There is a complete loss of function or mutant form of the receptor in 
individuals possessing the homozygous C/C condition (Poch et al., 2001). The buildup of 
angiotensin II results from AGTR1 malfunctioning. The lack of C/C genotype in this 
study was not surprising based upon the results of prior studies (Gillespie et al., 2005). 
Only heterozygote individuals carried the C allele for rs5186. In this study, the A/A 
genotype was the majority genotype, which indicates a functional angiotensin receptor is 
present in most Kasigau participants. The stage of EH does not appear to be associated 
with any particular allele or genotype of AGTR1 in this study and Kasigau overall. Allele 
and genotype frequencies were consistent with those observed in this study for all three 
sublocations of Kasigau.  
This study evaluated the HSD11β2 rs5479 SNP and the susceptibility of 
developing EH within an East African population. Previous studies have found that the A 
allele for rs5479 is rarer than the C allele (Friso, Pizzolo, Choi, Guarini, & Castagna, 
2008). The current study also found that the C allele was more abundant in Kasigau 
individuals with EH. Mutations of the C allele of rs5479 to the A variant has been shown 
to lead to extracellular volume expansion of the kidney and adrenal cortex (Friso et al., 
2008). Kasigau participants with Stage I and Stage II EH were more frequently found to 
possess the A/A genotype than that of normotensive participants in this study. 
Previous studies have identified RAS gene polymorphisms and EH within many 
ethnic groups (Deng, 2007), but none have thoroughly investigated EH in East African 
populations. There are many reasons for this exclusion, although many of the Kasigau 
results are comparable to other areas of the world. EH manifests itself universally as the 
most critical condition related to CVD (Edwards et al., 2000), regardless of the 
similarities, disparities, and differences that exist among ethnic groups and geography. 
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The EH severity, rates of CVD, and associated genotype data that were determined for 
other ethnic communities such as Japanese and European descendants (Wang, Poole, 
Treiber, Harshfield, & Hanevold, 2006) are similar to the distribution of alleles in 
Kasigau. From the International HapMap project (http://hapmap.ncbi.nlm.nih.gov), 
populations of people from African, American, East Asian, and European decent were 
used as sources of comparison. This database is not exclusive to RAS genes, but rather to 
each individual SNP selected for this study.  
Included in the HapMap project are subpopulations of participants with African 
ancestry, specifically Luhya in Webuye, Kenya and Yoruba in Ibadan, Nigeria. This 
ancestry is most relevant to the Kasigau data because of similar demographic and 
geographic origins. Nigerians are West African and had different ancestry during African 
migration. Therefore, the Luhya population is likely the most genetically similar to the 
participants from Kasigau. 
The allelic distribution data of rs699 for the overall Kasigau population was 
similar to the frequencies reported for Luhya. There were little differences discovered in 
the comparison of SNPs genotype distributions between Kasigau and Luhya, but the 
largest difference was discovered as a slightly higher C allele frequency was discovered 
for AGTR1 in Kasigau than in Luhya. Overall, individuals in the Kasigau population are 
least like individuals from the Southwest United States and Nigeria, the other two 
sublocations listed within the SNP comparison database as populations of African 
ancestry. 
This study also found that Bughuta, the most populated of the sublocations, had 
the least diverse genotype and allelic distribution. There was less genetic diversity in the 
most populated rural villages of Tanzania as well (Edwards et al., 2000). In parts of the 
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world with moderate to high rates of CVD, investigators have found no significant 
correlation between genetic diversity and susceptibility to CVD or changes in BP (Gupta 
et al., 2004). 
The results of the present study contribute critical information to a developing 
database of knowledge about EH, the RAS, and genetics of Kenyan people. This study 
relied on previously established parameters such as ancestral and susceptible alleles, 
frequencies of genotypes, frequencies of alleles, and other relevant details related to all 
three RAS gene SNPs. This study is among the first to study SNPs related to EH in East 
African populations. In the future, the results derived from this study will be used to help 
promote awareness and treatment of how genetic elements impact disease in developing 
countries. In addition to discovering more about the genetic components of RAS genes 
and their contributions to the development of EH within the people of Kenya, this study 
has implications for many additional areas of research.  
Finally, environment-gene interactions should also be evaluated. Epigenetic 
factors, gene-gender interactions, aging effects, and salt sensitivity have been shown to 
influence the development of EH (Mathers & Loncar, 2006) and need to be addressed in 
future studies. This is particularly relevant to Kasigau for the genetic SNPs and EH 
classification differences that resulted from this study.
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